Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management
Clinical Endocrinology, EarlyView.ABSTRACT Classic congenital adrenal hyperplasia (CCAH) is an autosomal recessive genetic disorder primarily caused by 21‐hydroxylase deficiency. Although the survival rate of patients has significantly improved with glucocorticoid replacement therapy, long‐term use of supraphysiological doses and multiple factors inherent to the disease itself have led
Jialin Mu +5 more
wiley +1 more source
Ozempic (semaglutide) versus Nonpharmacologic Interventions For Weight Management in Overweight Individuals [PDF]
Ozempic (semaglutide) is a medication prescribed for individuals managing Type 2 Diabetes Mellitus by mimicking the action of a hormone called GLP-1, helping to regulate glucose levels by stimulating insulin secretion and reducing glucagon secretion ...
DiGirolamo, Emma +4 more
core +1 more source
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer +1 more
wiley +1 more source
Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. [PDF]
Diabetes CareKarakus KE +10 more
europepmc +1 more source
Clinical Obesity, Volume 15, Issue 2, April 2025.Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton +4 more
wiley +1 more source
Reaching an ACCORD on Glycemia and Systolic Blood Pressure Targets in Type 2 Diabetes Mellitus [PDF]
, 2018 MacDonald, Thomas M., Mackenzie, Isla S.
core +2 more sources
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. [PDF]
Diabetes CareGaneshalingam AA +6 more
europepmc +1 more source
Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review
Diabetic Medicine, EarlyView.Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To characterize the cardiometabolic profiles of oral and subcutaneous glucagon‐like peptide‐1 (GLP‐1) receptor mono‐agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta‐analysis (NMA).
Ying Lu +8 more
wiley +1 more source